Literature DB >> 15585011

Evaluation of adrenal function in small-breed dogs receiving otic glucocorticoids.

R Ghubash1, R Marsella, G Kunkle.   

Abstract

The objectives of this study were to evaluate adrenal function after otic glucocorticoid [Tresaderm (dexamethasone) and Otomax (betamethasone)] therapy in small-breed dogs without evidence of otitis and to evaluate the length of time needed for resolution of adrenal suppression after discontinuation of treatment. Fourteen clinically healthy, privately owned, small-breed dogs with normal ears and normal adrenocorticotropin (ACTH) stimulation tests were assigned to one of two treatment groups, receiving one of the medications at the manufacturer's recommended dosage twice daily for 2 weeks. All of the dogs in the betamethasone treatment group had normal ACTH stimulation tests after 2 weeks of treatment. In contrast, 5/7 (71.43%) in the dexamethasone group, had suppressed adrenocortical responses to exogenous ACTH. Three of these five dogs (42%) returned to normal values 1 week after ceasing the medication and two (28.57%) returned to normal values 2 weeks after ceasing the medication. In conclusion, it appears that adrenal function can be suppressed for up to 2 weeks in dogs receiving otic dexamethasone. A follow-up study repeating this work in dogs with inflamed ears is needed before further clinical recommendations can be made.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585011     DOI: 10.1111/j.1365-3164.2004.00416.x

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  2 in total

1.  Use of topical glucocorticoids in veterinary dermatology.

Authors:  Frédéric Sauvé
Journal:  Can Vet J       Date:  2019-07       Impact factor: 1.008

Review 2.  Triangulation of pharmacoepidemiology and laboratory science to tackle otic quinolone safety.

Authors:  Almut G Winterstein; Patrick J Antonelli
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-10-25       Impact factor: 3.688

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.